• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Solventum (SOLV) Heads To Wells Fargo Conference As Undervalued View Stays In Focus

    Simply Wall St·09/15/2026 07:25:47
    语音播报

    Solventum (SOLV) is scheduled to present at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, in Boston, providing investors with updated insight into the recently listed healthcare specialist.

    At a share price of US$89.82, Solventum has delivered a 90 day share price return of 17.32% and a year to date share price return of 13.67%, while the 1 year total shareholder return of 22.69% points to building momentum ahead of the Wells Fargo appearance.

    Capitalize on the momentum around Solventum by scanning a curated list of solid balance sheet and fundamentals (23 results) that, like SOLV, pairs established healthcare operations with recent share price strength.

    Recent gains in Solventum highlight a tension between a firm with growing annual revenue and flat net income, and a stock that has rerated quickly. How far does the current valuation already bake that in?

    Most Popular Narrative: 4% Undervalued

    On the most followed view of Solventum, a fair value of $93.15 sits modestly above the last close at $89.82. This keeps the focus on how the separation story and margin path might justify that gap.

    The company's new product innovation pipeline (notably in Negative Pressure Wound Therapy, advanced wound care, sterilization, and digital health solutions such as autonomous coding) is gaining traction, positioning Solventum to benefit from rising global demand for technologically advanced healthcare equipment, ultimately supporting future topline and earnings growth.

    See why 31 investors see Solventum as 4% undervalued.

    The narrative uses an 8.1% discount rate and assumes revenue growth of roughly 2.7% a year with profit margins settling around 9.8%. It then applies a future P/E of 21.4x to those projected earnings to reach the $93.15 figure. That framework also factors in the planned Health Information Systems separation, ERP rollout and cost programs, which analysts see as key to how investors may eventually assess Solventum as a more focused MedTech business.

    Result: Fair Value of $93.15 (UNDERVALUED)

    Still, the ongoing separation of the Health Information Systems unit and the large ERP rollout could disrupt operations and margins, challenging the current Solventum narrative.

    Find out about the key risks to this Solventum narrative.

    Next Steps

    Mixed signals around Solventum's story so far, with both concerns and bright spots in view, mean the next move is yours. Act before sentiment shifts and weigh both sides of the ledger by reviewing the 3 key rewards and 3 important warning signs.

    Looking for more investment ideas beyond Solventum?

    If Solventum has your attention, broaden your opportunity set now by lining up a handful of fresh ideas before markets move on without you.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.